A phase 1/2 study of the menin inhibitor revumenib with the CELMod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias

Poster Presentation | Jun 13, 2026

Author

Chin KK, et al.

Congress

European Hematology Association Annual Congress 2026

Stockholm, Sweden | June 11 – 14, 2026